LACMED (5341) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of LACMED MYR 1.13, price MYR 0.71, upside +60.3%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch LACMED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 23, 2026.
How to read this chart
9‑month range 0.6500 MYR – 1.24 MYR · fair‑value band 0.8500 MYR – 1.42 MYR · the 0.7050 MYR price screens below the 1.13 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 23, 2026.
Follow LACMED in your weekly email
Every Wednesday you see whether LACMED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LAC Med Berhad engages in the distribution, supply, and integration of medical devices, diagnostic equipment, and digital health solutions for diagnostic purposes in Malaysia and Indonesia. The company offers diagnostic equipment, radiographic, ultrasound, magnetic resonance imaging (MRI), as well as software systems and maintenance services.
Show more
LAC Med Berhad engages in the distribution, supply, and integration of medical devices, diagnostic equipment, and digital health solutions for diagnostic purposes in Malaysia and Indonesia. The company offers diagnostic equipment, radiographic, ultrasound, magnetic resonance imaging (MRI), as well as software systems and maintenance services. It serves hospitals, clinics, and healthcare providers. The company was incorporated in 2003 and is headquartered in Petaling Jaya, Malaysia.
Stock analysis
LACMED (5341) currently trades at 0.7050 MYR, while our model-based Fair Value estimate is 1.13 MYR, implying the stock looks roughly 37.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1.32 MYR per share, and 11 of the 17 models we run sit above the 0.7050 MYR price.
Bear case: the Dividend Discount group reads lowest at 0.1400 MYR, and 6 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.8500 MYR (bear) to 1.42 MYR (bull), the price of 0.7050 MYR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
LACMED reported revenue of 202M MYR in FY2025 versus 107M MYR in FY2022, a compound +23.7%/yr. Reported net income was 21.9M MYR in FY2025, compounding +18.9%/yr from FY2022.
Key figures
Market cap 282M MYR (≈ $69.2M) · P/E ratio 14.1 · P/S ratio 1.53 · EPS (TTM) 0.0500 MYR · Dividend yield 1.0% · Net margin 10.9% · Return on equity 20.7% · Return on assets (EBIT) 17.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 60%, 5341 screens cheaper than that median.
Fair Value models
Bear 0.8500 MYRFair Value 1.13 MYRBull 1.42 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0316 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.1%
Dividend (yield on the price)1.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 16%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+60% · Top 25%
Profitability
Return on equity (TTM)21% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth−4% · Below median
Dividend yield (TTM)1.0% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "LACMED Fair Value". https://www.fairvalue-calculator.com/stock/5341
Frequently asked questions
Is LACMED (5341) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 1.13 MYR versus a price of 0.7050 MYR, about +60% upside (undervalued).
What is the fair value of 5341?
Our model-based fair value for LACMED is 1.13 MYR (as of Sep 23, 2026), built from audited fundamentals. The current price: 0.7050 MYR.
What is the quality score of 5341?
LACMED has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LACMED (5341)?
Our model-based price target is the fair value of 1.13 MYR (as of Sep 23, 2026) from 17 valuation models. Cautious scenario 0.8500 MYR, optimistic scenario 1.42 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the LACMED stock forecast for 2026?
Our models put fair value at 1.13 MYR, about +60% upside versus a price of 0.7050 MYR (undervalued). Cautious scenario 0.8500 MYR, optimistic scenario 1.42 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of LACMED (5341)?
LACMED reported trailing-twelve-month revenue of about 182M MYR (latest available figure, as of Sep 23, 2026).
Does LACMED pay a dividend?
LACMED currently shows a dividend yield of about 0.99% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of LACMED (5341)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LACMED it is 1.13 MYR per share (as of Sep 23, 2026), against a price of 0.7050 MYR. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is LACMED stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 5341 trades below its calculated fair value: price 0.7050 MYR, fair value 1.13 MYR, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5341?
No. The price is what the market pays today (0.7050 MYR); the fair value is what the company's own numbers justify (1.13 MYR). For LACMED the two are 0.4250 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is LACMED worth?
The market values LACMED at about 282M MYR (market capitalisation, as of Sep 23, 2026). Per share that is 0.7050 MYR; our models calculate a fair value of 1.13 MYR per share.
What do the bullish and bearish scenarios say about 5341?
Our models span a range for LACMED: cautious scenario 0.8500 MYR, base 1.13 MYR, optimistic 1.42 MYR per share (as of Sep 23, 2026, price 0.7050 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 5341?
LACMED trades at a price-to-earnings ratio of 14.1 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.13 MYR is built from several models across several years. Other multiples: P/B 0.6, P/S 0.4.
How solid is the balance sheet of LACMED (5341)?
Balance-sheet figures for LACMED (as of Sep 23, 2026): return on equity 20.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
Which stocks are comparable to LACMED?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LACMED stock attractive at the current price?
The data as of Sep 23, 2026: price 0.7050 MYR, calculated fair value 1.13 MYR (+60%), Quality Score 48/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5341 calculated?
We run LACMED through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.13 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. LACMED currently trades 60 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LACMED (5341)?
The closing price on Sep 24, 2026 was 0.7050 MYR. Our model-based fair value is 1.13 MYR, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LACMED right now?
The price is below even our cautious bear case (0.8500 MYR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of LACMED
How large is the market capitalisation of LACMED (5341)?
The market capitalisation of LACMED is 282M MYR (≈ $69.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LACMED (5341)?
The price-to-sales ratio of LACMED is 1.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LACMED (5341)?
Earnings per share at LACMED are 0.0500 MYR (price ÷ EPS = P/E 14.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LACMED (5341)?
The dividend yield of LACMED is 1.0% (payout 14.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LACMED (5341)?
The net margin of LACMED is 10.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LACMED (5341)?
The return on equity (ROE) of LACMED is 20.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LACMED (5341)?
On an EBIT basis the return on assets of LACMED is 17.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LACMED (5341)?
The operating margin of LACMED is 14.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LACMED (5341)?
Revenue at LACMED is growing −4.0% versus a year earlier (3y avg +23.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LACMED (5341)?
Earnings per share at LACMED are growing +4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LACMED (5341) generate?
The free cash flow of LACMED is −11.6M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LACMED (5341) carry?
The net debt of LACMED is 4.4M MYR (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch LACMED in the live analysis
One click puts LACMED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
